Samsung Biologics Acquires US Rockville Plant, Sales Reflected from H2 | Oh Wooseok Manager & Chesley Investment Advisory

Summary

Manager Oh Wooseok presents a bullish Kyobo Securities report on Samsung Biologics, detailing strong Q2 earnings, new plant contributions, an ambitious target price, and improved H2 visibility. CEO Park Se-ik and Analyst Choi Ho then discuss Samsung Biologics as a quality stock within the context of investment styles, cautioning against style drift while acknowledging its long-term stability.

• Samsung Biologics Q2 revenue 1.3 trillion won, operating profit 580 billion won, ~20-30% growth.
• Plants 1-4 fully operational; Plant 5 and Rockville plant to add revenue from Q3, supporting guidance upper end.
• Kyobo target price of 1,900,000 won based on 2027 EBITDA 3.4 trillion won and 24.5x multiple.
• Acquisition of Polypeptide Group diversifies modalities; company holds 2.2 trillion won in cash.
• Stock attracted buying after underperformance due to improved H2 earnings visibility.
• Discussion on quality stocks: Samsung Biologics seen as Korean quality name, but market style rotation is hard to time.
• Caution against style drift; long-term holdings may suit investors who prefer stable earners.